Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 data

18 September 2026 · By · Wire by Fusion42

Published

18 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at fiercebiotech.com →

◆ Verified

Fusion42 · 18 September 2026 · Fusion42 review

Bristol-Myers Squibb has discontinued development of Orum's degrader-antibody conjugate after evaluating initial Phase 1 data, abandoning a potential $100 million investment.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 18 Sep 2026 and 20 Sep 2026.

◆ ◆ The Wire takeaway

You face higher risk of rapid project cancellation in biotech partnerships like BMS abandoning Orum’s degrader. Prepare to pivot swiftly and reassess pipeline dependencies.

◆ Coverage

2 sources · first reported 18 Sep 2026 · latest 20 Sep 2026

◆ Related on Wire

◆ Topics

Biotechbmsdrug-terminationclinical-trialbiotech